Expanded access to ABBV-706
Part of Cancer, Lungs & breathing clinical trials.
This trial provides access to an investigational drug called ABBV-706 for people who have no other standard treatment options. It aims to offer treatment when no other clinical trials are available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- No other suitable standard treatments are available for your condition.
- You do not qualify for any ongoing clinical trials.
- You are willing to receive an investigational drug under an expanded access program.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ABBV-706 against standard treatments (topotecan, lurbinectedin, or amrubicin) for people with small cell lung cancer that has come back or stopped responding to previous therapies. The goal is to see if ABBV-706 works better at controlling the cancer.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This trial tests a new drug called IBI3009 for people with advanced small cell lung cancer that cannot be removed by surgery. It aims to see how safe the drug is and how well it works against the cancer.
This program provides access to an investigational drug for people who have already been part of the main clinical trial and have no other treatment options. It aims to give continued treatment when regular access is not possible.
This study tests an oral drug called ABBV-711, alone or with another drug, for adults with advanced squamous cell cancers of the head, neck, or lung that have stopped responding to standard treatments. It aims to see how safe and effective the drug is.
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.